Search
Olorofim
go.drugbank.com/drugs/DB15245InvestigationalOlorofim is under investigation in clinical trial NCT03340597 (Assessment of Varying Oral Dosing Regimens for F901318 in Healthy Subjects).
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 SubstratesAvutometinib
go.drugbank.com/drugs/DB15254ApprovedInvestigationalAvutometinib is a small molecule kinase inhibitor targeted against RAF/MEK1, key regulators of the RAS/RAF/MEK/ERK (MAPK) pathway. The MAPK pathway is implicated in variety of cancers, playing a key role in tumor cell proliferation, diff...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesRisdiplam
go.drugbank.com/drugs/DB15305ApprovedInvestigationalRisdiplam is an orally bioavailable mRNA splicing modifier used for the treatment of spinal muscular atrophy (SMA). It increases systemic SMN protein concentrations by improving the efficiency of SMN2 gene transcription. This mechanism o...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesVericiguat
go.drugbank.com/drugs/DB15456ApprovedInvestigationalVericiguat is a direct stimulator of soluble guanylate cyclase (sGC) used in the management of systolic heart failure to reduce mortality and hospitalizations. A key component of the NO-sGC-cGMP signaling pathway that helps to regulate t...
Categories: P-glycoprotein substratesYersinia pestis 195/p antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB15461InvestigationalYersinia pestis 195/p antigen (formaldehyde inactivated) is under investigation in clinical trial NCT02596308 (Immunogenicity and Safety of Subunit Plague Vaccine).
Synonyms: Yersinia pestis 195/p antigen (formaldehyde inactivated)Mexazolam
go.drugbank.com/drugs/DB15489InvestigationalMexazolam (CS-386) is a benzodiazepine indicated for the treatment of anxiety with or without psychoneurotic conditions. Mexazolam's structure is similar to that of other benzodiazepines such as oxazolam and cloxazolam. The use of benzod...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesSotorasib
go.drugbank.com/drugs/DB15569ApprovedInvestigationalSotorasib, also known as AMG-510, is an acrylamide-derived KRAS inhibitor developed by Amgen. It is indicated in the treatment of adult patients with KRAS G12C mutant non-small cell lung cancer. This mutation makes up >50% of all KRAS...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesFennel
go.drugbank.com/drugs/DB15615ApprovedCategories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2E1 InhibitorsUlotaront
go.drugbank.com/drugs/DB15665InvestigationalUnlike other drugs used for this condition, SEP-363856 does not bind to the dopamine D2 receptors, but exerts actions on the trace amine–associated receptor 1 (TAAR1) and 5-hydroxytryptamine type 1A (5
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 SubstratesEthyl biscoumacetate
go.drugbank.com/drugs/DB08794ApprovedWithdrawnEthyl biscoumacetate is a courmarin that is used as an anticoagulant. It has actions similar to those of Warfarin. (From Martindale, The Extra Pharmacopoeia, 30th ed, p226)
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates